Onconova Therapeutics, Inc. to Host Webcast Regarding Insights Into Rigosertib Mechanism of Action With Scientific Founder, Dr. E. Premkumar Reddy
NEWTOWN, Pa., Jan. 17, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it will webcast a presentation by Dr. E. Premkumar Reddy of recent studies regarding the mechanism of action for rigosertib. The webcast will take place on Friday, January 24th at 11:00 a.m. ET.
The live webcast will be available at this link or can be accessed by visiting "Events & Presentations" in the Investors and Media section of the Company's website at www.onconova.com. A recording of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.
CONTACT: Onconova Therapeutics
Benjamin Hoffman, 267-759-3680
bhoffman@onconova.us
Media:
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
chris@macbiocom.com
